Measurement of glomerular filtration rate in lung transplant recipients highlights a dramatic loss of renal function after transplantation.

chronic kidney disease epidemiology lung transplant measured GFR

Journal

Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 23 09 2019
accepted: 16 03 2020
entrez: 30 10 2020
pubmed: 31 10 2020
medline: 31 10 2020
Statut: epublish

Résumé

Chronic kidney disease (CKD) after lung transplantation (LT) is underestimated. The aim of the present study was to measure the loss of glomerular filtration rate (GFR) 1 year after LT and to identify the risk factors for developing Stage ≥3 CKD. LT patients in the University Hospital of Lyon had a pre- and post-transplantation measurement of their GFR (mGFR), and GFR was also estimated using the Chronic Kidney Disease Epidemiology Collaboration equation. During the study period, 111 patients were lung transplant candidates, of which 91 had a pre-transplantation mGFR, and 29 had a mGFR at 1 year after LT. Six patients underwent maintenance haemodialysis after transplantation. Mean mGFR was 106 mL/min/1.73 m The present study underlines the value of mGFR in the pre-LT stage and found major renal function loss after LT, and consequently two-thirds of patients have Stage ≥3 CKD at 1 year. All patients with a pre-LT mGFR <90 mL/min/1.73 m

Sections du résumé

BACKGROUND BACKGROUND
Chronic kidney disease (CKD) after lung transplantation (LT) is underestimated. The aim of the present study was to measure the loss of glomerular filtration rate (GFR) 1 year after LT and to identify the risk factors for developing Stage ≥3 CKD.
METHODS METHODS
LT patients in the University Hospital of Lyon had a pre- and post-transplantation measurement of their GFR (mGFR), and GFR was also estimated using the Chronic Kidney Disease Epidemiology Collaboration equation.
RESULTS RESULTS
During the study period, 111 patients were lung transplant candidates, of which 91 had a pre-transplantation mGFR, and 29 had a mGFR at 1 year after LT. Six patients underwent maintenance haemodialysis after transplantation. Mean mGFR was 106 mL/min/1.73 m
CONCLUSION CONCLUSIONS
The present study underlines the value of mGFR in the pre-LT stage and found major renal function loss after LT, and consequently two-thirds of patients have Stage ≥3 CKD at 1 year. All patients with a pre-LT mGFR <90 mL/min/1.73 m

Identifiants

pubmed: 33123359
doi: 10.1093/ckj/sfaa053
pii: sfaa053
pmc: PMC7577765
doi:

Types de publication

Journal Article

Langues

eng

Pagination

828-833

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.

Références

Clin Biochem. 2017 May;50(7-8):385-393
pubmed: 28108166
Clin Transplant. 2017 May;31(5):
pubmed: 28196295
Clin Kidney J. 2016 Oct;9(5):682-99
pubmed: 27679715
Nephrol Dial Transplant. 2019 Jan 1;34(1):118-122
pubmed: 29684175
Am J Transplant. 2017 Jan;17 Suppl 1:357-424
pubmed: 28052607
N Engl J Med. 2003 Sep 4;349(10):931-40
pubmed: 12954741
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3
pubmed: 2520314
Transplant Proc. 2015 Jul-Aug;47(6):1966-71
pubmed: 26293082
Kidney Int. 1996 Oct;50(4):1089-100
pubmed: 8887265
Clin Kidney J. 2016 Oct;9(5):700-4
pubmed: 27679716
Clin J Am Soc Nephrol. 2014 Apr;9(4):720-7
pubmed: 24482068
Ann Hum Genet. 1955 Jun;19(4):251-3
pubmed: 14388528
J Heart Lung Transplant. 2015 Oct;34(10):1264-77
pubmed: 26454740
J Ren Nutr. 2017 Nov;27(6):470-473
pubmed: 29056168
Eur J Clin Pharmacol. 2017 May;73(5):573-580
pubmed: 28132082

Auteurs

Nans Florens (N)

Université de Lyon, CarMeN, INSERM U1060, INSA de Lyon, Université Claude Bernard Lyon 1, INRA U1397, Villeurbanne, France.
Hospices Civils de Lyon, Service de Néphrologie, Hôpital E. Herriot, Lyon, France.

Laurence Dubourg (L)

Hospices Civils de Lyon, Service de Néphrologie, Hôpital E. Herriot, Lyon, France.

Laurent Bitker (L)

Hospices Civils de Lyon, Service de Néphrologie, Hôpital E. Herriot, Lyon, France.

Emilie Kalbacher (E)

Hospices Civils de Lyon, Service de Néphrologie, Hôpital E. Herriot, Lyon, France.

François Philit (F)

Hospices Civils de Lyon, Hôpital L. Pradel, Bron, F-69500, France.
UMR754 INRA Université Lyon 1, Université de Lyon, Lyon, France.

Jean François Mornex (JF)

Hospices Civils de Lyon, Hôpital L. Pradel, Bron, F-69500, France.
UMR754 INRA Université Lyon 1, Université de Lyon, Lyon, France.

François Parant (F)

Department of Pharmacology, Hospices Civils de Lyon, Hôpital Lyon Sud, Lyon, France.

Fitsum Guebre-Egziabher (F)

Université de Lyon, CarMeN, INSERM U1060, INSA de Lyon, Université Claude Bernard Lyon 1, INRA U1397, Villeurbanne, France.
Hospices Civils de Lyon, Service de Néphrologie, Hôpital E. Herriot, Lyon, France.

Laurent Juillard (L)

Université de Lyon, CarMeN, INSERM U1060, INSA de Lyon, Université Claude Bernard Lyon 1, INRA U1397, Villeurbanne, France.
Hospices Civils de Lyon, Service de Néphrologie, Hôpital E. Herriot, Lyon, France.

Sandrine Lemoine (S)

Université de Lyon, CarMeN, INSERM U1060, INSA de Lyon, Université Claude Bernard Lyon 1, INRA U1397, Villeurbanne, France.
Hospices Civils de Lyon, Service de Néphrologie, Hôpital E. Herriot, Lyon, France.

Classifications MeSH